menu
    • menu
    [{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Bivigam","moa":"Fc receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADMA Biologics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"ADMA Biologics \/ Undisclosed"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Morgan Stanley"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Undisclosed"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Undisclosed"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Morgan Stanley"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"RI-002","moa":"IgG","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADMA Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ADMA Biologics \/ Undisclosed"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"ADMA Biologics \/ Undisclosed"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor||Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Undisclosed"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor||Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by ADMA Biologics

    Menu

    ADMA Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age ...

                            Details : FDA Approved Bivigam (immune globulin intravenous, human), a plasma-derived, polyclonal, intravenous immune globulin, for the treatment of primary humoral immunodeficiency in pediatric patient aged 2 years or older.

                            Product Name : Bivigam

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 12, 2023

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®

                            Details : BIVIGAM (immune globulin intravenous, human – 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). BIVIGAM was approved by the FDA in May 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI).

                            Product Name : Bivigam

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 13, 2022

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Raymond James & Associates, Inc.

                            Deal Size : $69.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Opt...

                            Details : BIVIGAM (human immune globulin, 10% liquid) is indicated for the treatment of primary humoral immunodeficiency. This includes, the humoral immune defect in CVID, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and SC...

                            Product Name : Bivigam

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 09, 2022

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Raymond James & Associates, Inc.

                            Deal Size : $69.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Raymond James & Associates, Inc.

                            Deal Size : $60.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

                            Details : BIVIGAM [Immune Globulin Intravenous (Human), 10% Liquid] is indicated for the treatment of primary humoral immunodeficiency (PI). This includes the humoral immune defect in CVID, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldric...

                            Product Name : Bivigam

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Raymond James & Associates, Inc.

                            Deal Size : $60.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Globulin,Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV at CIS 2022

                            Details : ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-derived, polyclonal, intravenous IVIG, indicated for treatment of primary humoral immunodeficiency, also known as primary immune deficiency disease, in adults and adolescents.

                            Product Name : Asceniv

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 01, 2022

                            Lead Product(s) : Immune Globulin,Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Globulin,Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV & BIVIGAM from 24 to 36 Months

                            Details : Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM immune globulin (“IG”) drug product stored at 2-8°C, in all vial sizes, production scales as well as internal and external fill-finished drug product.

                            Product Name : Asceniv

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 25, 2022

                            Lead Product(s) : Immune Globulin,Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Raymond James & Associates, Inc.

                            Deal Size : $57.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ O...

                            Details : ADMA intends to use the net proceeds from this offering (i) to advance the commercial sales of its U.S. Food and Drug Administration (FDA)-approved products through the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV.

                            Product Name : Bivigam

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 25, 2021

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Raymond James & Associates, Inc.

                            Deal Size : $57.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Raymond James & Associates, Inc.

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock

                            Details : ADMA intends to use the net proceeds from this offering to advance the commercial sales of its U.S. Food and Drug Administration (FDA)-approved products through the procurement of raw materials for the manufacturing of BIVIGAM® and ASCENIV™.

                            Product Name : Bivigam

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 21, 2021

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Raymond James & Associates, Inc.

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Globulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIVâ„¢ (IGIV...

                            Details : Asceniv (Immune Globulin) is a Other Large Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Primary Immunodeficiency Diseases.

                            Product Name : Asceniv

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 07, 2021

                            Lead Product(s) : Immune Globulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ADMA Biologics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Morgan Stanley

                            Deal Size : $94.6 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option

                            Details : ADMA intends to use the net proceeds from this offering (i) for the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV.

                            Product Name : Bivigam

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 24, 2020

                            Lead Product(s) : Human Immunoglobulin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Morgan Stanley

                            Deal Size : $94.6 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth